LXEO

Lexeo Therapeutics Inc

3.14

Oct 30 • 3:59 PM ET +0.08 (2.61%)

3.14

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: TNYA RCKT RNA LRMR DSGN RGNX SLDB QURE FDMT TSHA

| Held by: VTI IWM XBI VXF IWN KOMP IBB DFAS VTWO FESM

Scroll to Statements

Index	RUT
Market Cap	257.76M
Enterprise Value	52.87M
Income	-87.27M
Sales	0.00M
Book/sh	2.99
Cash/sh	2.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	59
IPO	Nov 03, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.05
P/C	1.22
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.89
Current Ratio	13.89
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.16
EPS next Y	-1.34
EPS next Q	-0.32
EPS this Y	36.08%
EPS next Y	-12.34%
EPS next 5Y	13.49%
EPS past 3/5Y	5.73% -57.31%
Sales past 3/5Y	- -
EPS Y/Y TTM	64.51%
Sales Y/Y TTM	-
EPS Q/Q	49.57%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-5.19% -

Insider Own	15.83%
Insider Trans	-0.54%
Inst Own	100.04%
Inst Trans	7.53%
ROA	-40.50%
ROE	-46.76%
ROIC	-36.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.30%
SMA50	-16.31%
SMA200	-39.74%
Trades

Shs Outstand	78.62M
Shs Float	69.09M
Short Float	25.41%
Short Ratio	13.63
Short Interest	17.55M
52W High	10.99 -71.43%
52W Low	2.55 23.14%
Volatility	10.72% 8.74%
ATR (14)	0.27
RSI (14)	48.26
Beta	1.65
Rel Volume	0.78
Avg Volume	1.29M
Volume	1,001,523

Perf Week	12.14%
Perf Month	-13.26%
Perf Quarter	-25.24%
Perf Half Y	-45.58%
Perf YTD	-68.38%
Perf Year	-66.70%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.11
Target Price	20.67
Prev Close	3.06
Price	3.14
Change %	2.61%

Consensus

Strong Buy

Avg. Price Target

$20.67

Implied Upside

+558.3%

Analysts11incl. previous ratings

Rating Distribution11 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 18, 2025	Initiated	RRaymond James	Strong Buy	$25	+696.2%
Nov 20, 2025	Initiated	CCantor Fitzgerald	Overweight	$19	+505.1%
Oct 15, 2025	Initiated	GGuggenheim	Buy	$30	+855.4%
Jul 31, 2025	Initiated	OOppenheimer	Outperform	$20	+536.9%
Jun 13, 2024	Initiated	RRobert W. Baird	Outperform	$28	+791.7%
Jun 06, 2024	Initiated	HH.C. Wainwright	Buy	$22	+600.6%
Nov 28, 2023	Initiated	SStifel	Buy	$20	+536.9%
Nov 28, 2023	Initiated	RRBC Capital Mkts	Outperform	$22	+600.6%
Nov 28, 2023	Initiated	LLeerink Partners	Outperform	$19	+505.1%
Nov 28, 2023	Initiated	JJP Morgan	Overweight	$20	+536.9%
Nov 28, 2023	Initiated	CChardan Capital Markets	Buy	$23	+632.5%

Oct-19-26 07:00AM	Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM (GlobeNewswire)
Oct-08-26 07:00AM	Lexeo Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire)
Oct-01-26 09:00AM	Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) (GlobeNewswire) +7.10%
Sep-23-26 08:00AM	Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia (PR Newswire) -13.51%
07:00AM	Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum (GlobeNewswire)
07:00AM	Loading…
Sep-22-26 07:00AM	Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia (GlobeNewswire)
Sep-02-26 07:00AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-26 07:00AM	Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-26 07:00AM	Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy (GlobeNewswire)
Jun-17-26 04:01PM	Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia (GlobeNewswire)
Jun-15-26 07:00AM	Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia (GlobeNewswire) +6.41%
May-19-26 07:00AM	Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-11-26 07:00AM	Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
Apr-27-26 05:15PM	Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
Mar-30-26 04:05PM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (GlobeNewswire) +8.92%
07:30AM	Loading…
Mar-03-26 07:30AM	Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-28-26 04:06PM	Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference (MarketBeat)
Feb-14-26 03:11AM	Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit (MarketBeat)
Feb-05-26 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February (GlobeNewswire) -5.23%
Feb-02-26 09:54AM	H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program (Insider Monkey)
Jan-27-26 07:30AM	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics (GlobeNewswire)
Jan-12-26 07:00AM	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy (GlobeNewswire) -22.96%
Jan-09-26 06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive) +11.30%
Jan-08-26 07:00AM	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy (GlobeNewswire) -5.49%
Dec-27-25 07:28AM	Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline (Insider Monkey)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
Dec-22-25 07:30AM	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 08:00AM	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Nov-11-25 09:55AM	Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know (Zacks) +7.04%
Nov-05-25 07:36AM	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
05:32AM	Loading…
Nov-03-25 05:32AM	Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim's Stock Picks with Huge Upside Potential (Insider Monkey) -9.69%
Oct-26-25 06:05AM	Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise (Insider Monkey)
Oct-23-25 09:55AM	Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? (Zacks)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-20-25 04:05PM	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering (GlobeNewswire)
Oct-17-25 09:27AM	Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 (Insider Monkey) +9.24%
Oct-16-25 11:29PM	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement (GlobeNewswire)
04:32PM	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 06:00AM	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +28.90%
Aug-14-25 07:30AM	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Jul-31-25 09:46AM	Meta, Microsoft upgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:23AM	Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) (Insider Monkey)
Jul-07-25 07:00AM	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia (GlobeNewswire)
Jun-24-25 07:30AM	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics (GlobeNewswire) +6.31%
May-27-25 07:31AM	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases (GlobeNewswire)
May-12-25 07:00AM	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
May-01-25 09:16AM	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) +19.85%
Apr-07-25 06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study (GlobeNewswire) -23.34%
Mar-25-25 09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat) +8.56%
08:44AM	Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? (Insider Monkey)
Mar-24-25 07:00AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +50.92%
Jan-07-25 07:30AM	Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer (GlobeNewswire) -5.03%
Dec-02-24 07:00AM	Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 (Business Wire)
Nov-13-24 07:30AM	Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 06:14AM	Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -17.00%
Oct-22-24 07:30AM	Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference (GlobeNewswire)
Sep-05-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Jul-16-24 11:03AM	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data (Zacks)
Jul-15-24 04:17PM	Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion (Investor's Business Daily) -26.08%
10:11AM	Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout (Investor's Business Daily)
06:36AM	Lexeo gene therapy shows signs of heart benefit in small study (BioPharma Dive)
06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire)
Jul-11-24 08:00AM	Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 (GlobeNewswire) +6.08%
Jul-08-24 07:00AM	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors (GlobeNewswire) +5.55%
May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tamayo Louis Edward	Chief Financial Officer	Aug 18 '26	Sale	4.91	4,117	20,203	92,907	Aug 19 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 18 '26	Sale	4.95	3,345	16,562	374,472	Aug 19 05:00 PM
Otero Jose Manuel	Chief Operating Officer	Aug 18 '26	Sale	4.96	1,304	6,464	136,178	Aug 19 05:00 PM
Townsend Richard Nolan	Officer	Aug 18 '26	Proposed Sale	4.95	3,345	16,562		Aug 18 03:16 PM
Otero Jose Manuel	Officer	Aug 18 '26	Proposed Sale	4.96	1,304	6,464		Aug 18 03:12 PM
Tamayo Louis Edward	Officer	Aug 18 '26	Proposed Sale	4.91	4,117	20,203		Aug 18 03:09 PM
Tamayo Louis Edward	Chief Financial Officer	Jul 01 '26	Sale	4.49	4,641	20,838	97,024	Jul 01 06:49 PM
Otero Jose Manuel	Chief Operating Officer	Jul 01 '26	Sale	4.48	4,666	20,904	137,482	Jul 01 06:49 PM
Bhalla Narinder Pal	Chief Medical Officer	Jul 01 '26	Sale	4.42	22,306	98,593	82,194	Jul 01 06:48 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 01 '26	Sale	4.48	25,947	116,243	377,817	Jul 01 06:47 PM
Otero Jose Manuel	Officer	Jul 01 '26	Proposed Sale	4.48	4,666	20,919		Jul 01 04:54 PM
Tamayo Louis Edward	Officer	Jul 01 '26	Proposed Sale	4.49	4,641	20,815		Jul 01 04:43 PM
Bhalla Narinder Pal	Officer	Jul 01 '26	Proposed Sale	4.42	22,306	98,684		Jul 01 04:43 PM
Townsend Richard Nolan	Officer	Jul 01 '26	Proposed Sale	4.48	25,947	116,185		Jul 01 04:41 PM
Otero Jose Manuel	Chief Operating Officer	May 18 '26	Sale	5.07	1,302	6,606	130,088	May 20 04:30 PM
Townsend Richard Nolan	Chief Executive Officer	May 18 '26	Sale	5.06	3,342	16,927	336,764	May 20 04:30 PM
Townsend Richard Nolan	Officer	May 18 '26	Proposed Sale	5.06	3,342	16,927		May 18 03:41 PM
Otero Jose Manuel	Officer	May 18 '26	Proposed Sale	5.07	1,302	6,606		May 18 03:26 PM
Adler Eric	Officer	May 18 '26	Proposed Sale	5.06	1,595	8,074		May 18 03:26 PM
Townsend Richard Nolan	Chief Executive Officer	Apr 06 '26	Sale	5.69	55,000	313,137	340,106	Apr 07 04:55 PM
Richard Nolan Townsend	Director	Apr 06 '26	Proposed Sale	5.72	55,000	314,600		Apr 06 04:11 PM
Otero Jose Manuel	Chief Operating Officer	Feb 18 '26	Sale	6.40	3,016	19,294	125,460	Feb 20 05:05 PM
Townsend Richard Nolan	Chief Executive Officer	Feb 18 '26	Sale	6.38	10,173	64,924	392,483	Feb 20 05:05 PM
Townsend Richard Nolan	Officer	Feb 18 '26	Proposed Sale	6.38	11,374	72,585		Feb 18 04:26 PM
Otero Jose Manuel	Officer	Feb 18 '26	Proposed Sale	6.40	3,016	19,294		Feb 18 03:51 PM
See Tai Sandi	Officer	Feb 18 '26	Proposed Sale	6.39	3,861	24,684		Feb 18 03:34 PM
Robertson Jenny	Officer	Feb 18 '26	Proposed Sale	6.40	3,736	23,897		Feb 18 03:28 PM
Adler Eric	Officer	Feb 18 '26	Proposed Sale	6.40	4,867	31,135		Feb 18 03:28 PM
Townsend Richard Nolan	Chief Executive Officer	Nov 18 '25	Sale	9.27	1,127	10,447	240,991	Nov 20 05:21 PM
Adler Eric	Chief Medical Officer	Nov 18 '25	Sale	9.27	615	5,701	72,646	Nov 20 05:20 PM
See Tai Sandi	Chief Development Officer	Nov 18 '25	Sale	9.27	386	3,578	65,476	Nov 20 05:19 PM
Robertson Jenny	Chief Legal Officer	Nov 18 '25	Sale	9.27	549	5,089	68,381	Nov 20 05:18 PM
Robertson Jenny	Officer	Nov 18 '25	Proposed Sale	9.27	549	5,092		Nov 18 03:45 PM
See Tai Sandi	Officer	Nov 18 '25	Proposed Sale	9.27	386	3,580		Nov 18 03:38 PM
Otero Jose Manuel	Officer	Nov 18 '25	Proposed Sale	9.27	721	6,687		Nov 18 03:37 PM
Adler Eric	Officer	Nov 18 '25	Proposed Sale	9.27	615	5,704		Nov 18 03:31 PM
Townsend Richard Nolan	Officer	Nov 18 '25	Proposed Sale	9.27	1,127	10,452		Nov 18 03:12 PM

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

CEO & DirectorMr. R. Nolan Townsend M.B.A.

CFO & Principal Accounting OfficerMr. Louis Tamayo

Co-FounderDr. Ronald G. Crystal M.D.

Chief Operating OfficerDr. Jose Manuel Otero Ph.D.

FSCAIDr. Narinder P. Bhalla FACC

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc

Upgrade your Finviz experience